Francois Ringeisen

TL;DR: BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.

TL;DR: Mutation analysis of plasma-derived cfDNA by ddPCR suggests that PFS benefit of everolimus was maintained irrespective of PIK3CA genotypes, consistent with the previous analysis of archival tumour DNA by next-generation sequencing.

TL;DR: It is shown that multiple factors affect the tumorigenic potential of FGFR1, thus providing clinical hypotheses for refinement of patient selection and suggesting implications for patient selection for treatment with FGFR inhibitors.

TL;DR: The marked PFS improvement in patients receiving EVE + EXE as first-line therapy for disease recurrence during or after (neo)adjuvant NSAI therapy supports the efficacy of this combination in the first- line setting.

TL;DR: In a meta-analysis of clinical studies, stomatitis did not adversely affect PFS in everolimus-treated patients, and in some studies, trended toward longer PFS than in patients without stom atitis.